Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Dopaminergic Drugs Cause Changes in Deep Brain Areas of Parkinson’s Patients

By NWO | December 2, 2016

A drug like levodopa, which is used by patients with Parkinson’s disease, causes changes in the communication between deep brain areas that are important for learning and behavior.

In Parkinson’s disease, the functioning of cells in the substantia nigra of the brain is disrupted. Accumulation of the protein alpha-synuclein plays an important role. The cells gradually die, a dopamine deficit arises in the brain and the regulatory circuits become disrupted. This gives rise to a wide range of symptoms such as tremors and stiffness. The process of protein accumulation and cell mortality cannot be prevented, but the dopamine can be supplemented via drugs. This reduces the symptoms, even though the effect is often only temporary.

Such ‘dopaminergic’ drugs have their own side effects. The substance levodopa, for example, which is one of the best-known Parkinson drugs, can cause impulse control disorders in patients. These include such disorders as gambling or sexual addiction. Payam Piray investigated the correlation between the use of the drugs and the behavioural changes in the patient.

Learning and behavior

Piray: ‘Using refined computational techniques, we have demonstrated that with the use of dopaminergic drugs, people are no longer able to adequately learn from the positive and negative consequences of their behaviour. With the help of computational and brain scanning techniques, we discovered that these drugs alter the communication between the deep brain areas that are important for learning and behaviour. The exact effect depends on how impulsive a patient is before he or she starts taking the drugs: dopamine-stimulating drugs increase brain communication in people with an impulsive personality, but reduce it in people who are not impulsive by nature.’

This research illustrates the power of combining the computational and brain sciences, says Piray. ‘As a consequence, we are able to better understand the brain and behaviour. Nearly all effects in this research could be isolated thanks to the use of computational techniques. Without those techniques, we might have concluded that dopaminergic drugs have little effect on our brain and behaviour. Now we know how such drugs work in the brain, which consequences they have on behaviour and whom this affects.’

Related Articles Read More >

professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
Health-related innovation in Morocco highlighted by resident inventor patenting activity
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE